Gilead Sciences IncGILD:NSQ

74.08
0.22 / 0.30%
22.10m
46.49%
0.6545
Close in USDToday's changeShares traded1 year changeBeta
As of Apr 24 2014 21:00 BST.Data delayed by at least 15 minutes.

Consensus recommendation

As of Apr 18, 2014, the consensus forecast amongst 32 polled investment analysts covering Gilead Sciences, Inc. advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Oct 21, 2009. The previous consensus forecast advised investors to purchase equity in Gilead Sciences, Inc..

Previous recommendations
Last year3 months ago2 months ago4 weeks agoLatest
Mouseover chart recommendation details.
Latest recommendation
Buy13
Outperform11
Hold7
Underperform0
Sell0
No opinion0

Research Reports

Ford Investor Services, Inc.
MarketLine (a Datamonitor Company)

Share price forecast

The 24 analysts offering 12 month price targets for Gilead Sciences, Inc. have a median target of 97.50, with a high estimate of 132.00 and a low estimate of 65.00. The median estimate represents a 32.01% increase from the last price of 73.86. View Full Financials

High+82.2 %135.00
Med+29.6 %96.00
Low-29.8 %52.00

Dividends

Dividend information is not available for Gilead Sciences Inc. View Full Financials

Earnings history & estimates

On Apr 22, 2014, Gilead Sciences, Inc. reported 1st quarter 2014 earnings of 1.48 per share. This result exceeded the 0.91 consensus of the 25 analysts covering the company and exceeded last year's 1st quarter results by 1.00. View Full Interim Financials

Average growth rate+45.76%

Gilead Sciences, Inc. reported annual 2013 earnings of 2.04 per share on Feb 04, 2014. View Full Annual Financials

Average growth rate+10.28%
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement

Revenue

Gilead Sciences Inc. had 1st quarter 2014 revenues of 5.00bn. This bettered the 3.98bn consensus of the 21 analysts covering the company. This was 60.23% above the prior year's 1st quarter results. View Full Interim Financials

Average growth rate+20.55%

Gilead Sciences Inc. had revenues for the full year 2013 of 11.20bn. This was 15.45% above the prior year's results. View Full Annual Financials

Average growth rate+12.51%
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.